Inhibikase Adjusts and Terminates Stock Offering Agreement

Inhibikase Therapeutics ( (IKT) ) has provided an announcement.

Inhibikase Therapeutics entered an At the Market Offering Agreement with H.C. Wainwright & Co. to sell shares of its common stock up to $5.66 million. They sold 315,338 shares for $849,187.85 but later reduced the sale limit to $50,000 and ultimately terminated the agreement effective December 11, 2024. This move reflects strategic adjustments in their stock offering endeavors.

For an in-depth examination of IKT stock, go to TipRanks’ Stock Analysis page.